| Autor: |
Nicolas Hanset, Emmanuel Esteve, Emmanuelle Plaisier, Catherine Johanet, Pierre-Antoine Michel, Jean-Jacques Boffa, Patrick Fievet, Laurent Mesnard, Johann Morelle, Pierre Ronco, Karine Dahan |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Kidney International Reports, Vol 5, Iss 3, Pp 331-338 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2468-0249 |
| DOI: |
10.1016/j.ekir.2019.12.006 |
| Popis: |
Introduction: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membranous nephropathy. Whether its use is also appropriate in patients with an estimated glomerular filtration rate |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
